Chugai to Replace Restricted Stock with Trust-Based Equity Incentive Plan

Chugai Pharmaceutical Co ( (JP:4519) ) has issued an update.

Chugai Pharmaceutical has decided to abolish its existing restricted stock compensation system for directors, executive officers and employees, as well as for directors and employees of its subsidiaries, and replace it with a trust-based stock compensation framework designed to better align management and staff incentives with medium- to long-term performance and corporate value. The new structure will use a Board Incentive Plan Trust for directors and an Employee Stock Ownership Plan Trust for employees, delivering company shares and equivalent cash based on predefined share delivery regulations, and will require approval at upcoming general shareholder meetings; once adopted, no new restricted stock will be issued under the old plan, though already granted shares will remain in place and the company aims to operate the new trusts on an ongoing basis through renewals and additional contributions.

The most recent analyst rating on (JP:4519) stock is a Buy with a Yen9900.00 price target. To see the full list of analyst forecasts on Chugai Pharmaceutical Co stock, see the JP:4519 Stock Forecast page.

More about Chugai Pharmaceutical Co

Chugai Pharmaceutical Co., Ltd., listed on the Prime Market of the Tokyo Stock Exchange, is a Japan-based pharmaceutical company focused on the research, development and commercialization of prescription medicines, with a strategic emphasis on innovative therapies that support its medium- to long-term corporate value growth.

Average Trading Volume: 2,301,476

Technical Sentiment Signal: Buy

Current Market Cap: Yen14209.7B

For detailed information about 4519 stock, go to TipRanks’ Stock Analysis page.